Digital reminiscence app aims to lift mood in dementia
NCT ID NCT07237009
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether daily 10-15 minute personalized reminiscence sessions delivered by a digital app can improve symptoms like apathy and depression in older adults with mild neurocognitive disorders. Eighty participants over 60 will use the app for 25 days, with a caregiver helping to personalize memories. The goal is to see if this approach can boost mood, motivation, sleep, and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants will be recruited during routine visits at five French university hospital geriatrics/memory clinics. The source population comprises older adults followed in these services who live mainly at home or in hospital-based residential settings. The study focuses exclusively on patients with mild neurocognitive disorder or mild dementia, and includes individuals with mild depression.
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men and women over 60 years of age. * DSM-5 diagnosis: Early stage of major neurocognitive disorders or MCI (Mild Cognitive Impairment) including all underlying causes. * Have a Mini-Mental State Exam score of 21 ≤ MMSE ≤ 28. * Presence of mild or moderate depression, or presence of mild or moderate apathy, or presence of both * Displays the necessary physical and cognitive abilities, without major limitations compromising interaction with the digital tool. * Having voluntarily and informedly agreed to participate in the study (signed written consent). * Subject's ability to hear and see the digital tool's stimuli (tests integrated into the tool). * Patients with access to an Apple device (smartphone or tablet), either personal or provided by the sponsor, running iOS version 16 or higher, with internet access. * Patient has at least one close referent who declares their wish to contribute to the collection of biographical information via the digital messaging group. * Subjects covered by a social security scheme. Exclusion Criteria: * Patients with moderate or severe dementia (MMSE score ≤ 20) because implicit memory recall is less effective in moderate or severe stages for people with PWD. * Presence of major psychiatric disorders (e.g., schizophrenia, severe major depressive episode, bipolar disorder). * Major hearing or visual impairments. * History of premorbid intellectual disability. * Patients under guardianship, conservatorship, or legal protection. * Patients who have already used the Lilia app * Participating simultaneously in another study involving human subjects, a clinical investigation, or a therapeutic trial for the entire duration of the study. * Patients who have received a new treatment related to neurocognitive disorders (medication) during the 3 months prior to the inclusion visit.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
APHP Hôpitaux universitaires Paris centre.
NOT_YET_RECRUITINGParis, 75013, France
-
CHU Angers, Service médecine gériatrique.
RECRUITINGAngers, 49 933, France
-
CHU DE TOURS, Pôle Vieillissement, Hôpital Bretonneau.
RECRUITINGTours, 37044, France
-
Centre Hospitalier Universitaire de Nice - Institut Claude Pompidou, Centre Mémoire de Ressources et de Recherches (CM2R)
RECRUITINGNice, 06100, France
-
Limoges University Hospital Center - Dupuytren Hospital], Geriatric medicine department
RECRUITINGLimoges, 87042, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can brain scans unlock the mystery of apathy?
- Could a common ADHD drug reawaken motivation?
- Your voice may hold clues to depression – a new device listens in
- Could the sound of your voice reveal depression?
- Can a simple exercise program boost brain and balance in aging minds?
- Could a virtual activity-based therapy lift teen depression?